Skip to main content

Table 1 Basic characteristics of the study population (n = 747)

From: Do newly marketed generic medicines expand markets using descriptive time series analysis and mixed logit models? Korea as an exemplar and its implications

 

Total Sample

Previously treated

Newly treated

P-value

 

(N = 747)

(N = 283)

(N = 464)

Sex (male, %)

35.2

34.6

35.5

NS

Age (years), mean(SD)

61.62(11.06)

62.96(9.76)

60.84(11.72)

0.0078

Age group, N(%)

    

 Less than 50

99(13.2)

26(9.2)

73(15.7)

 

 50 ~ 59

209(28.0)

82(29.0)

127(27.4)

 

 60 ~ 69

244(32.7)

112(39.6)

132(28.5)

 

 70+

135(26.1)

63(22.3)

132(28.5)

 

Insurance status, N(%)

   

NS

 NHI

698(93.1)

259(91.5)

439(94.6)

 

 Medical Aid

49(6.6)

24(8.5)

25(5.4)

 

Education, N(%)

   

NS

Before or Primary school

112(15.4)

36(13.0)

76(16.8)

 

 Middle school

261(35.8)

105(38.0)

156(34.5)

 

 High school

133(18.2)

52(18.8)

81(17.9)

 

 College +

223(30.6)

83(30.1)

140(30.9)

 

Visits by type of institutions, N(%) a

 

 Tertiary general hospital

126(16.8)

24(16.1)

42(13.5)

0.0375

 General hospital

180(24.1)

47(31.5)

61(13.2)

NS

 Hospital

76(10.2)

9(6.0)

46(14.7)

0.0073

 Clinics

424(56.7)

163(57.6)

261(56.1)

NS

 Others

54(7.2)

12(4.2)

42(9.0)

0.0141

Major comorbidities, N(%)

    

 Hypertension

534(71.5)

245(86.6)

289(62.3)

<0.0001

 Diabetes

345(46.2)

167(59.0)

178(38.4)

<0.0001

 Stroke

135(18.1)

59(20.9)

76(16.4)

NS

 Depression

68(9.1)

30(10.6)

38(8.2)

NS

 Osteoporosis

120(17.5)

61(21.6)

59(12.7)

0.0014

No. of visits per users during observational period

  
 

9.34(8.37)

13.95(9.36)

6.55(6.23)

<0.0001

  1. aPercent may be over 100 %